Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| A1Cantus | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The investigators will conduct a randomized controlled 2-arm parallel trial of A1c Drink vs. Placebo over a 3-month period and compare changes in Ha1c from baseline to 3 months. Investigator and study personnel, as well as participants, will be blinded to drink assignments.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo Drink | Placebo Comparator | The placebo drink will be formulated to closely match the active drink in taste, color and mouthfeel, while removing all active ingredients. |
|
| A1C Drink | Experimental | The A1C drink is currently on the market with natural active ingredients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A1C Drink | Dietary Supplement | In the experimental arm, participants will drink the A1C drink BID for 3 months as instructed. Both the active and placebo drinks will be identical in can size (12 oz slim can), packaging format, and visual appearance. |
| Measure | Description | Time Frame |
|---|---|---|
| Hemoglobin A1C | Change in Ha1c from baseline to 3 months. To test the efficacy of the A1Cantus drink in improving glycemic control in patients with Type II Diabetes | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in A1C | Percentage of participants whose A1C was lowered from Baseline to 3 months | 3 months |
| Hypertension | Change in systolic and diastolic blood pressure from baseline to three months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Elizabeth Jacobs, MD, MPP | Contact | 951-827-8643 | elizabeth.jacobs@medsch.ucr.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UCR Health | Riverside | California | 92521 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Centers for Disease Control and Prevention. (2026) National Diabetes Statistics Report, 11 Mar 2026. Available at https://gis.cdc.gov/grasp/diabetes/diabetesatlas-statsreport.html. | ||
| 37255779 | Background | Lorestanifar M, Mosayebi Molasaraei M, Jashaninejad R, Khoshmanesh S, Doosti-Irani A. The prevalence of uncontrolled diabetes mellitus in patients with type 2 diabetes: a multicenter cross-sectional study. J Diabetes Metab Disord. 2023 Mar 17;22(1):787-792. doi: 10.1007/s40200-023-01201-9. eCollection 2023 Jun. | |
| Background | https://diabetes.org/about-diabetes/complications |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo drink | Other | In the placebo arm, participants will drink the placebo drink BID for 3 months as instructed. Both the active and placebo drinks will be identical in can size (12 oz slim can), packaging format, and visual appearance. |
|
| 3 months |
| Body Mass Index (BMI) | Change in body mass index from baseline to 3 months | 3 months |
| Cholesterol | Change in fasting LDL and HDL from baseline to three months | 3 months |
| D004700 | Endocrine System Diseases |